Skip to content
OpenCapital
Get started

ADC Therapeutics ADCT Q4 2025 Annual earnings

Reported March 10, 2026 · Before market open

Revenue$23.1MBeat by $757.8K
EPS-$0.04Beat by $0.28
Revenue estimate$22.3M
EPS estimate-$0.32

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$18.9M
EPS estimate-$0.19

Versus estimates

Revenue

Q1 2026$20.9MBeat by $864.2K
Q4 2025$23.1MBeat by $757.8K
Q3 2025$16.4MMiss by $5.1MQ2 2025$18.8MBeat by $645.5KQ1 2025$23.0MBeat by $5.5MQ4 2024$16.9MMiss by $2.1M

Diluted EPS

Q1 2026-$0.21Miss by $0.02
Q4 2025-$0.04Beat by $0.28
Q3 2025-$0.30Beat by $0.10Q2 2025-$0.50Miss by $0.14Q1 2025-$0.36Beat by $0.02Q4 2024-$0.29Beat by $0.06

Ask the moment ADC Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ADC Therapeutics report Q4 2025 earnings?
ADC Therapeutics (ADCT) reported Q4 2025 earnings on March 10, 2026 before market open.
What were ADC Therapeutics's Q4 2025 revenue and EPS?
ADC Therapeutics reported revenue of $23.1M and eps of $-0.04 for Q4 2025.
Did ADC Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $22.3M by $757.8K. EPS beat the consensus estimate of $-0.32 by $0.28.
How did ADC Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 36.4% from $16.9M a year earlier and eps grew 86.2% from $-0.29.
Where can I find ADC Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-016238) and the 10-K periodic report (0001628280-26-016491) directly on SEC EDGAR. The filing index links above go to sec.gov.